PHIO (RXi Pharmaceuticals) הכנסות חזויות של החברה
The key driver for Phio Pharmaceuticals (PHIO) is the INTASYL platform for creating self-delivering RNA interference in immuno-oncology. The company's expected sales volume on the GURU.Markets daily chart reflects the dynamics of this potential, where 0.00 captures the magnitude of this parameter. Preclinical in vivo tests to mitigate risks and the prospects of strategic alliances with the largest pharma behemoths in the untapped niche of precision therapy further strengthen the fundamentals.
פילוחי נתונים אנליטיים מרוכזים עבור Phio Pharmaceuticals Corp. (PHIO)
Investors assess an asset's operational resilience through the ratio of market capitalization to expected revenue. For Phio Pharmaceuticals (PHIO), the automation of oligonucleotide synthesis via robotics increases drug development precision, impacting future earnings. By analyzing the company's projected sales volume, you can see the dependence of the current share price on expected cash flows. This metric measures market expectations regarding the commercialization of technologies. The indicator's trend confirms the financial viability of the business model.
